Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsOPHTHALMICGeneric

POLY-PRED

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

Standard Dose
EQ 0.35% BASE;10,000 UNITS/ML;0.5%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview POLY-PRED is listed in Drugs@FDA under application 050081 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE Form and strength SUSPENSION/DROPS;OPHTHALMIC - EQ 0.35% BASE;10,000 UNITS/ML;0.5% Sponsor ALLERGAN Submission history Latest submission status date: 2003-03-19 00:00:00.

Structured Monograph

Clinical summary

Approval overview POLY-PRED is listed in Drugs@FDA under application 050081 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE Form and strength SUSPENSION/DROPS;OPHTHALMIC - EQ 0.35% BASE;10,000 UNITS/ML;0.5% Sponsor ALLERGAN Submission history Latest submission status date: 2003-03-19 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.